A fit adult has metastatic colorectal adenocarcinoma. Molecular and clinical review concludes that available targeted treatments and immunotherapy are...

Question

A fit adult has metastatic colorectal adenocarcinoma. Molecular and clinical review concludes that available targeted treatments and immunotherapy are unsuitable, but fluoropyrimidine-based chemotherapy would otherwise be offered as second-line treatment. Which addition is now a routine NICE option?

Accepted Answer

Add bevacizumab to the planned second-line fluoropyrimidine-based chemotherapy

Answer

Add cetuximab to the planned fluoropyrimidine regimen as the default biological

Answer

Use bevacizumab alone after discontinuing the planned fluoropyrimidine-based chemotherapy

Answer

Reserve bevacizumab with fluoropyrimidine chemotherapy until the fourth treatment line

Answer

Add nivolumab to fluoropyrimidine chemotherapy despite the negative immunotherapy assessment

Perioperative Atrial Fibrillation — MRCP Part 1 MCQ